Global Information
회사소개 | 문의 | 비교리스트

안과용 약물전달 : 시장 개요, 전달 기술, 제휴 기회 - 제2판(2020년)

Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities, 2nd Edition (2020)

리서치사 MCD Group, LLC
발행일 2020년 11월 상품 코드 960900
페이지 정보 영문 199 Pages
가격
US $ 5,950 ₩ 7,070,000 PDF (Corporate License)


안과용 약물전달 : 시장 개요, 전달 기술, 제휴 기회 - 제2판(2020년) Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities, 2nd Edition (2020)
발행일 : 2020년 11월 페이지 정보 : 영문 199 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

눈물점 마개, 안구 삽입물, 장기지속형 주사제·임플란트, 국소 시스템, 나노입자, 일렉트로포레이션 및 새로운 투여 기기의 기술 등 안과용 약물전달 개선에 이용 가능한 40개 이상의 기술 개요를 제공합니다.

목차

서론

제1장 안과 질환

  • 노인황반변성(AMD)
  • 황반부종과 당뇨망막병증
  • 녹내장
  • 염증성 질환
  • 안구건조증

제2장 시장 개요

  • 주요 기업

제3장 안과용 약물전달 상황

  • 비침습적 전달 기술
  • 침습적 전달 기술
  • 인가된 안구 DDS 제품
  • 안구 DDS 파이프라인
  • 녹내장
  • 포도막염과 황반부종
  • 눈염증
  • 노인황반변성
  • 안구건조증
  • 새로운 치료법과 적응증
  • 개발 기회
  • 향후 전망

제4장 기술 개요

  • 새로운 에어로졸과 점안약
    • Aero Pump
    • CIS Pharma
    • Eyenovia
    • Kedalion Therapeutics
    • Nemera
    • Zeteo Biomedical
  • 눈물점 마개와 안구 삽입물
    • AesculaTech
    • Amorphex Therapeutics
    • BioLight Life Sciences
    • Eximore
    • Mati Therapeutics
    • Ocular Therapeutix
  • 국소 전달 시스템
    • 20/20 OptimEyes
    • Aciont
    • EyeCRO
    • EyeGate Pharma
    • Integral Ophthalmics
    • iView Therapeutics
    • Kala Pharmaceuticals
    • Nanomerics
    • Novaliq
    • Oculis
    • MC2 Therapeutics
    • MuPharma
    • Santen Pharmaceuticals
    • Sun Ophthalmics
    • Surface Pharmaceuticals
    • TALLC
    • TearClear
  • 주사제와 임플란트
    • 3T Ophthalmics
    • Abbvie
    • Aerie Pharmaceuticals
    • Clearside Biomedical
    • Congruence Medical
    • DelSiTech
    • EyePoint Pharmaceuticals
    • Eyevensys
    • Glaukos
    • Graybug Vision
    • iVeena Delivery Systems
    • Kodiak Biosciences
    • LayerBio
    • Nanogenics
    • Neurotech Pharmaceuticals
    • OcuJect
    • PolyActiva
    • Re-Vana Therapeutics
    • Roche
    • TLC Bio
    • VisusNano
  • 약물 방출 렌즈
    • Glint Pharmaceuticals
    • Leo Lens Pharma
    • OcuMedic

제5장 대학의 기술

  • Johns Hopkins University : 망막 이식 기기
  • Johns Hopkins University : 소관 전달 시스템
  • Ohio State University : 2층 캡슐
  • Stanford University : 주사가능 변형가능 하이드로겔
  • University of Colorado : 나노겔 눈 전달 기기
  • University of Florida : 올레오겔 기술
  • University of Michigan : PLGA 코팅된 안구 임플란트
  • University of North Carolina : 세리아 나노입자
  • University of Pittsburgh : CyteSolutions Lens
  • University of Pittsburgh : 리버스 서멀 젤
KSM 20.12.18

This report includes profiles of 40+ technologies which can be utilized to improve ocular delivery. Examples of technologies covered: punctal plugs, ocular inserts, long-acting injectables and implants, topical systems, nanoparticles, electroporation as well as novel administration devices.

Each profile will contain the following information:

  • Company summary
  • Technology description
  • Patents/Publications
  • Development Status/Pipeline
  • Competitive Advantages
  • Partnering Opportunities
  • Company Contact Information

Table of Contents

Introduction

Chapter I: Eye Diseases

  • Age-Related Macular Degeneration (AMD)
  • Macular Edema and Diabetic Retinopathy
  • Glaucoma
  • Inflammatory Conditions
  • Dry Eye Disease

Chapter II: Market Overview

  • Key Players

Chapter III: Ophthalmic Drug Delivery Landscape

  • Non-Invasive Delivery Technologies
  • Invasive Delivery Technologies
  • Approved Ocular DDS Products
  • Ocular DDS Pipeline
  • Glaucoma
  • Uveitis and Macular Edema
  • Ocular Inflammation
  • Age-Related Macular Degeneration
  • Dry Eye Disease
  • Novel Therapies & Indications
  • Development Opportunities
  • Future Perspectives

Chapter IV: Technology Profiles

  • Novel Aerosol & Eye Drop Devices
    • Aero Pump
    • CIS Pharma
    • Eyenovia
    • Kedalion Therapeutics
    • Nemera
    • Zeteo Biomedical
  • Punctal Plugs & Ocular Inserts
    • AesculaTech
    • Amorphex Therapeutics
    • BioLight Life Sciences
    • Eximore
    • Mati Therapeutics
    • Ocular Therapeutix
  • Topical Delivery Systems
    • 20/20 OptimEyes
    • Aciont
    • EyeCRO
    • EyeGate Pharma
    • Integral Ophthalmics
    • iView Therapeutics
    • Kala Pharmaceuticals
    • Nanomerics
    • Novaliq
    • Oculis
    • MC2 Therapeutics
    • MuPharma
    • Santen Pharmaceuticals
    • Sun Ophthalmics
    • Surface Pharmaceuticals
    • TALLC
    • TearClear
  • Injectables & Implants
    • 3T Ophthalmics
    • Abbvie
    • Aerie Pharmaceuticals
    • Clearside Biomedical
    • Congruence Medical
    • DelSiTech
    • EyePoint Pharmaceuticals
    • Eyevensys
    • Glaukos
    • Graybug Vision
    • iVeena Delivery Systems
    • Kodiak Biosciences
    • LayerBio
    • Nanogenics
    • Neurotech Pharmaceuticals
    • OcuJect
    • PolyActiva
    • Re-Vana Therapeutics
    • Roche
    • TLC Bio
    • VisusNano
  • Drug Eluting Lenses
    • Glint Pharmaceuticals
    • Leo Lens Pharma
    • OcuMedic

Chapter V: University Technologies

  • Johns Hopkins University: Retinal Implantation Device
  • Johns Hopkins University: Canalicular Delivery System
  • Ohio State University: Bi-layered Capsule
  • Stanford University: Injectable Deformable Hydrogels
  • University of Colorado: Nanogel Ophthalmic Delivery Devices
  • University of Florida: Oleogel Technology
  • University of Michigan: PLGA-Coated Ocular Implants
  • University of North Carolina: Ceria Nanoparticles
  • University of Pittsburgh: CyteSolutions Lens
  • University of Pittsburgh: Reverse Thermal Gels

Table & Figures

  • Figure 1: Eye Disease Prevalence, US
  • Table 1: Wet AMD Therapeutics
  • Table 2: Injectable Steroids for Macular Edema
  • Table 3: Topical Glaucoma Products
  • Table 4: Ocular Anti-inflammatory Products
  • Table 5: Prescription Dry Eye Treatments
  • Figure 2: US Ophthalmic Market by Product Type, 2019
  • Table 6: Top-Selling Prescription Ophthalmic Products, 2019
  • Figure 3: Ophthalmic Revenues of Key Players, 2019
  • Figure 4: Key Players with Ocular DDS Products
  • Table 7: Comparison of Non-Invasive Ocular DDS
  • Figure 5: Durysta® Injector and Implant
  • Table 8: Comparison of Invasive Ocular DDS
  • Table 9: Approved Ophthalmic DDS Products, US
  • Figure 6: Timeline for Approved SR Ocular Implants in the US
  • Table 10: Topical Glaucoma DDS Pipeline
  • Table 11: Sustained Release Glaucoma Pipeline
  • Figure 7: Clearside Bio SCS Microinjector
  • Table 12: Uveitis and Macular Edema DDS Pipeline
  • Table 13: Ocular Pain and Inflammation DDS Pipeline
  • Table 14: Macular Degeneration DDS Pipeline
  • Table 15: Dry Eye DDS Pipeline
  • Table 16: Novel Therapies Pipeline
  • Table 17: Examples of Ophthalmic Candidates for Long-Acting Delivery
  • Figure 8: Medspray Spray Nozzle Unit
  • Figure 9: CIS Pharma Connected Dispenser
  • Figure 10: Eyenovia Microdose Dispenser
  • Table 18: Eyenovia Pipeline
  • Table 19: Optejet vs. Standard Eye Dropper
  • Figure 11: Depiction of AcuStream Patient Administration
  • Table 20: Kedalion Pipeline
  • Figure 12: e-Novelia Smart Add-On
  • Figure 13: AquilaMD Ophthalmic Device
  • Figure 14: AesculaGel and Applicator
  • Figure 15: TODDD matrix
  • Figure 16: TODDD drug depots
  • Table 21: Amorphex Pipeline
  • Table 22: TODDD Competitive Comparison
  • Figure 17: Eximore punctal plug
  • Table 23: Eximore Pipeline
  • Figure 18: Inserting the Evolute plug
  • Table 24: Mati Therapeutics Pipeline
  • Figure 19: Punctum Plug Depot
  • Table 25: Ocular Therapeutix Pipeline
  • Figure 20: Visulex-P Applicator
  • Figure 21: Visulex-I Platform and General Visulex Process
  • Figure 22: Aciont MRI study
  • Table 26: Aciont Pipeline
  • Figure 23: MiDROPS illustration
  • Figure 24: CMHA-S composition
  • Table 27: EyeGate Pipeline
  • Table 28: iView Pipeline
  • Figure 25: Proprietary Attributes of AMMPLIFY Technology
  • Table 29: Kala Pipeline
  • Figure 26: MET Design and Process
  • Table 30: Novaliq Pipeline
  • Table 31: Santen Ophthalmic DDS Pipeline
  • Table 32: Sun Ophthalmic DDS Products
  • Table 33: Surface Pharmaceuticals Pipeline
  • Figure 27: SmartCelle Delivery Schematic
  • Table 34: TALLC Pipeline
  • Figure 28: Diagram of Common Ocular Drug Delivery Systems
  • Figure 29: Visual of the Episcleral System
  • Table 35: 3T Product Pipeline
  • Figure 30: Photographs of the Sustained Release Bimatoprost SR Implant
  • Figure 31: PRINT technology
  • Table 36: Aerie Pipeline
  • Figure 32: SCS Microinjector
  • Table 37: Clearside Biomedical Pipeline
  • Figure 33: MDS Shown with Various 1 mL Long Prefillable Syringes
  • Figure 34: Durasert Implant
  • Table 38: EyePoint Pipeline
  • Table 39: Eyevensys Pipeline
  • Figure 35: Two Generations of iDose Implants
  • Table 40: Glaukos Pipeline
  • Figure 36: Graybug Microparticle Depot
  • Table 41: Graybug Pipeline
  • Figure 37: iVeena Bioerodible Implant
  • Figure 38: Kodiak ABC Platform
  • Figure 39: Molecular Properties of KSI-301
  • Table 42: Kodiak ABC Pipeline
  • Figure 40: LayerForm Assembly
  • Figure 41: PolyNet Illustration
  • Table 43: LayerBio Pipeline
  • Figure 42: ECT Platform Schematic
  • Table 44: Neurotech Pipeline
  • Figure 43: Classes of Therapeutics Supported by ECT Technology
  • Figure 44: SteriCap Mini Needle
  • Table 45: PolyActiva Ophthalmic Pipeline
  • Figure 45: EyeLief Mechanism of Drug Release
  • Table 46: Benefits of Re-Vana Delivery Systems
  • Figure 46: The PDS Implant in Position
  • Figure 47: Injection Demonstration for TLC399
  • Figure 48: Schematic of Leo Lens MediPrint Process
  • Table 47: Leo Lens Pipeline
  • Table 48: Leo Lens Technology Advantages
  • Figure 49: OcuMedic Novel Lens Technology
  • Table 49: OcuMedic Pipeline
Back to Top
전화 문의
F A Q